4.7 Review

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

Journal

BIOMARKER RESEARCH
Volume 9, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40364-021-00333-5

Keywords

Myeloid-derived suppressor cells; Tumor; Immunotherapy

Funding

  1. National Science Foundation of China [81974414, 81772788, 81873430]

Ask authors/readers for more resources

MDSC play vital roles in cancer microenvironment, influencing the responses to immunotherapies and prognosis of cancer patients. Therefore, proposing MDSC-inhibiting strategies becomes crucial in the field of cancer immunotherapies.
Myeloid-derived suppressor cells (MDSC) are a group of immature cells that produced by emergency myelopoiesis. Emerging evidences have identified the vital role of MDSC in cancer microenvironment, in which MDSC exerts both immunological and non-immunological activities to assist the progression of cancer. Advances in pre-clinical research have provided us the understanding of MDSC in cancer context from the perspective of molecular mechanism. In clinical scenario, MDSC and its subsets have been discovered to exist in peripheral blood and tumor site of patients from various types of cancers. In this review, we highlight the clinical value of MDSC in predicting prognosis of cancer patients and the responses of immunotherapies, therefore to propose the MDSC-inhibiting strategy in the scenario of cancer immunotherapies. Phenotypes and biological functions of MDSC in cancer microenvironment are comprehensively summarized to provide potential targets of MDSC-inhibiting strategy from the aspect of molecular mechanisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available